Move comes 2 years after controversial exit of brand-name product ...

Do the Compromises of Hatch-Waxman Need a Further Look? In Teva Pharmaceuticals Industries, Ltd. v. Crawford, decided this June, the U.S. Court of Appeals for the District of Columbia, in affirming a ...

One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.

Add Yahoo as a preferred source to see more of our stories on Google. Starting January 1, a drug that thousands of patients depend on to help them breathe will disappear from pharmacy shelves, and ...

The Federal Trade Commission is expected to release a comprehensive study on the competitive impact of authorized generic drugs in early 2010, while a new report concludes these versions of drugs ...

Amneal is debuting an authorized generic of Jazz Pharmaceuticals' Xyrem (Sodium Oxybate) oral solution CIII. Sodium Oxybate oral solution, 0.5 g/ml is a central nervous system depressant indicated for ...

Hello, and welcome to a health podocy. I'm your host, Rob Lott. I'll admit that I have a relatively simple understanding of the relationship between brand name drugs and generic drugs. Generally, I ...

Tapentadol immediate release tablets are used to manage acute pain severe enough to require an opioid analgesic.

A box of the asthma medication Flovent HFA. The branded version of the product is being discontinued and replaced by an authorized generic. (Photo by Smith Collection/Gado/Getty Images) Medicaid has a ...

Prescription drug advertising can be downright comical. Between middle-aged men petting dogs on the banks of rivers in cholesterol drug ads, and narrators rattling off a litany of potential side ...

(RTTNews) - Specialty pharmaceutical company Collegium Pharmaceutical, Inc. (COLL) announced Monday it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc., pursuant to ...

TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.